Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-10 pm EDT 5-day change 1st Jan Change
24.42 USD -3.67% Intraday chart for Rocket Pharmaceuticals, Inc. -3.97% -18.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102 MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target MT
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia CI
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO MT
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer CI
Rocket Pharmaceuticals, Inc. Announces Executive Appointments CI
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating MT
Rocket Pharmaceuticals Q4 Loss Narrows MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi DJ
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I) CI
Transcript : Rocket Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Certain Common Stock of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Warrants of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Restricted Stock Units of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Certain Stock Options of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023. CI
Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director CI
Rocket Pharmaceuticals Insider Sold Shares Worth $450,646, According to a Recent SEC Filing MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cantor Fitzgerald Initiates Rocket Pharmaceuticals With Overweight Rating, Price Target is $65 MT
Rocket Pharmaceuticals Insider Sold Shares Worth $315,744, According to a Recent SEC Filing MT
Rocket Pharmaceuticals' Biologics License Application for Gene Therapy Accepted by US FDA for Priority Review MT
Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I) CI
Chart Rocket Pharmaceuticals, Inc.
More charts
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
25.35 USD
Average target price
50.31 USD
Spread / Average Target
+98.45%
Consensus
  1. Stock Market
  2. Equities
  3. RCKT Stock
  4. News Rocket Pharmaceuticals, Inc.
  5. UBS Adjusts Rocket Pharmaceuticals Price Target to $62 From $68, Maintains Buy Rating